Anne Dejean-Assémat

From Wikipedia, the free encyclopedia
Anne Dejean-Assémat
Anne Dejean en 2019.jpg
Born (1957-01-06) 6 January 1957 (age 64)
Cholet, France
EducationPierre-and-Marie-Curie University
EmployerPasteur Institute, INSERM
Known forHuman cancers, Biology
AwardsMember of the French Academy of Sciences, Grand Prix INSERM, Sjöberg Prize
Websitehttps://research.pasteur.fr/en/team/nuclear-organization-and-oncogenesis/

Anne Dejean-Assémat is a French molecular biologist working on the mechanisms leading to the development of human cancers.[1] As Research Director at INSERM and Professor at the Pasteur Institute,[2] she heads the Laboratory of Nuclear Organization and Oncogenesis[3] at the Pasteur Institute and the INSERM Unit 993 'Molecular and Cellular Biology of Tumors'.

Biography[]

Anne Dejean-Assémat was educated at the Pierre and Marie Curie University in Paris, graduating with a Master of Science degree in Genetics in 1981. She then earned her PhD in Virology at the Pasteur Institute in 1988. Her thesis topic was the role of integrated hepatitis B virus sequences in the development of  hepatocellular carcinoma.[4] Since 2003, she has been leading the Nuclear Organization and Oncogenesis Unit at the Pasteur Institute. Anne Dejean-Assémat has held several scientific administration positions at the Scientific Council and as a president of the Genetics, Development and Cancer committee at INSERM (2008–2012) and in a study section at the French Ministry of Research and Technology. In 2004, she became a member of the French Academy of Sciences. She received the Prize L'Oréal-Unesco for Women in Science in 2010,[5] the Grand Prix INSERM, 2014 and the Sjöberg Prize, 2018.

Scientific contributions[]

A molecular biologist, Anne Dejean-Assémat investigates the mechanisms, at the genetic, epigenetic and cellular levels, responsible for the development of human cancers. Anne Dejean-Assémat and her collaborators have made important advances in understanding the origin of certain cancers and have opened up unique perspectives for new differentiation and targeted therapy leads.

She discovered mutations in the genes encoding the receptors for retinoic acid, the active derivative of vitamin A, in liver cancer and some types of leukemia and dissected the molecular mechanisms underlying their role in oncogenesis and treatment sensitivity. Her main contributions are the first demonstration of a direct role for the hepatitis B virus in human liver cancer as an insertional mutagen,[6] the discovery of a gene encoding a retinoic acid receptor at a hepatitis B virus integration site[7] and the molecular cloning of the PML-RAR oncoprotein responsible for acute promyelocytic leukemia.[8]

Focusing on the cellular defects characterizing this type of leukemia, she then discovered the implication of a novel cellular organelle, the PML Nuclear Body, and clarified the mechanisms underlying the high efficiency of acute promyelocytic leukemia treatment by retinoic acid and arsenic[9][10] which leeds to cure in more than 95% of the patients. Together, her studies led to the identification of the genetic and cellular mechanisms responsible for a human leukemia and to the understanding of the unique efficacy of this anti-tumor therapy targeted on the genetic defect. Her most recent work aims at eludicating the role of the post-translational modification by the SUMO protein in the epigenetic[11] control of gene expression.

Manipulation of experimental data supporting research articles published by Anne Dejean-Assémat's team has been reported in several cases.[12][13][14]

3 retractions listed at the Retraction Watch Database. http://retractiondatabase.org/RetractionSearch.aspx#?auth%3dDejean%252c%2bAnne

Society membership[]

Awards and honors[]

References[]

  1. ^ "Anne Dejean-Assémat, is awarded the Inserm Grand Prix for 2014". Newsroom | Inserm. 2014-11-26. Retrieved 2021-08-27.
  2. ^ Institut Pasteur. "Members of Institut Pasteur". research.pasteur.fr/. Archived from the original on 2016-10-11. Retrieved 2016-01-31.
  3. ^ Institut Pasteur. "Nuclear Organization and Oncogenesis". research.pasteur.fr/. Archived from the original on 2016-10-11. Retrieved 2016-01-31.
  4. ^ Dejean-Assemat, Anne (1988-01-01). Virus de l'hepatite b et hepatocarcinome : structure et role des sequences virales integrees (thesis thesis). Paris 6. Archived from the original on 2018-10-08. Retrieved 2019-09-11.
  5. ^ Jump up to: a b "Le 12Ème Prix L'Oréal-Unesco Pour Les Femmes Et La Science Est Attribué À 5 Femmes D'Exception Dont Une Chercheuse Française – L'Oréal Groupe". www.loreal.ca (in French). Archived from the original on 2021-05-14. Retrieved 2019-09-11.
  6. ^ Dejean, A.; Bougueleret, L.; Grzeschik, K. H.; Tiollais, P. (1986-07-03). "Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma". Nature. 322 (6074): 70–72. Bibcode:1986Natur.322...70D. doi:10.1038/322070a0. ISSN 0028-0836. PMID 3014347. S2CID 4355348.
  7. ^ Brand, N.; Petkovich, M.; Krust, A.; Chambon, P.; de Thé, H.; Marchio, A.; Tiollais, P.; Dejean, A. (1988-04-28). "Identification of a second human retinoic acid receptor". Nature. 332 (6167): 850–853. Bibcode:1988Natur.332..850B. doi:10.1038/332850a0. ISSN 0028-0836. PMID 2833708. S2CID 4349193.
  8. ^ de Thé, H.; Lavau, C.; Marchio, A.; Chomienne, C.; Degos, L.; Dejean, A. (1991-08-23). "The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR". Cell. 66 (4): 675–684. doi:10.1016/0092-8674(91)90113-d. ISSN 0092-8674. PMID 1652369. S2CID 40272758.
  9. ^ Weis, K.; Rambaud, S.; Lavau, C.; Jansen, J.; Carvalho, T.; Carmo-Fonseca, M.; Lamond, A.; Dejean, A. (1994-01-28). "Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells". Cell. 76 (2): 345–356. doi:10.1016/0092-8674(94)90341-7. ISSN 0092-8674. PMID 8293468. S2CID 36801773.
  10. ^ Müller, S.; Matunis, M. J.; Dejean, A. (1998-01-02). "Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus". The EMBO Journal. 17 (1): 61–70. doi:10.1093/emboj/17.1.61. ISSN 0261-4189. PMC 1170358. PMID 9427741.
  11. ^ Decque, Adrien; Joffre, Olivier; Magalhaes, Joao G.; Cossec, Jack-Christophe; Blecher-Gonen, Ronnie; Lapaquette, Pierre; Silvin, Aymeric; Manel, Nicolas; Joubert, Pierre-Emmanuel (February 2016). "Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing". Nature Immunology. 17 (2): 140–149. doi:10.1038/ni.3342. ISSN 1529-2916. PMID 26657003. S2CID 12081749.
  12. ^ Caudalis, Lymanopoda; et al. (4 November 2019). "Comments on "Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways"". pubpeer.com. Archived from the original on 7 November 2019. Retrieved 21 November 2019.
  13. ^ Caudalis, Lymanopoda; et al. (4 November 2019). "Comments on "The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis"". pubpeer.com. Archived from the original on 7 November 2019. Retrieved 21 November 2019.
  14. ^ Languida, Amphidoma; et al. (10 November 2019). "Comments on "Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity"". pubpeer.com. Archived from the original on 3 August 2020. Retrieved 21 November 2019.
  15. ^ "Anne Dejean-Assémat | Liste des membres de l'Académie des sciences / D | Listes par ordre alphabétique | Listes des membres | Membres | Nous connaître". www.academie-sciences.fr. Archived from the original on 2019-02-26. Retrieved 2019-09-11.
  16. ^ "The European Academy of Cancer Sciences | European Academy of Cancer Sciences". www.europeancanceracademy.eu. Archived from the original on 2019-07-04. Retrieved 2019-09-11.
  17. ^ "French foundation for cancer research – Donate Cancer research, cancer charity in france | Institut Curie Paris". institut-curie.org. Archived from the original on 2021-05-14. Retrieved 2019-09-11.
  18. ^ "Term 1999–2000 award winners – Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences – HMA". hmaward.org.ae. Archived from the original on 2021-05-14. Retrieved 2019-09-11.
  19. ^ "Fondation ARC pour la recherche sur le cancer | Fondation ARC". www.fondation-arc.org. Archived from the original on 2019-08-03. Retrieved 2019-09-11.
  20. ^ "Ligue contre le cancer | Association de lutte contre le Cancer". www.ligue-cancer.net. Archived from the original on 2019-09-24. Retrieved 2019-09-11.
  21. ^ "Lauréats des Prix INSERM 2014". inserm.fr. Archived from the original on 2016-02-16.
  22. ^ "Décret du 13 juillet 2016 portant promotion et nomination". Archived from the original on 2016-08-22.
  23. ^ "2018's Sjöberg Prize awarded for unique treatment that cures a once fatal cancer". The Royal Swedish Acacdemy of Science. 5 February 2018. Archived from the original on 10 July 2018.
Retrieved from ""